ESMO 2022 | Upcoming updates in GU cancers at ESMO 2022

Matthew Campbell, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on his highlights presented in the field of genitourinary cancer at the European Society for Medical Oncology (ESMO) 2022 Congress, including the Phase III COSMIC-313 trial (NCT03937219) of cabozantinib in combination with nivolumab and ipilimumab in advanced or metastatic renal cell carcinoma. Dr Campbell additionally comments on pembrolizumab and enfortumab vedotin in urothelial carcinoma. This interview took place at the ESMO 2022 Congress in Paris, France.